Natera, Inc. - Common Stock (NQ:NTRA)

420.78 +10.43 (+2.54%)

Delayed Quote Updated: 2:53 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests ↗

August 10, 2026

This sale was executed under a pre-arranged Rule 10b5-1 trading plan.

Via The Motley Fool

Topics Regulatory Compliance

Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know ↗

August 10, 2026

This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting.

Via The Motley Fool

Topics Regulatory Compliance

A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It ↗

August 10, 2026

This was a non-discretionary sale to cover tax withholding on vesting equity awards under a Rule 10b5-1 plan.

Via The Motley Fool

Topics Regulatory Compliance

Natera (NASDAQ:NTRA) Beats Q2 Estimates, Raises Full-Year Revenue Guidance ↗

August 06, 2026

Via Chartmill

A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know ↗

August 10, 2026

Sheena executed 9,150 shares under a pre-established trading plan adopted in December 2025.

Via The Motley Fool

Topics Regulatory Compliance

Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead. ↗

August 08, 2026

Druckenmiller only owns one "Magnificent Seven" stock.

Via The Motley Fool

Topics Artificial Intelligence

NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth

August 07, 2026

Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $752.8...

Via StockStory

Natera Q2 Earnings Call Highlights ↗

August 07, 2026

Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth...

Via MarketBeat

Topics Earnings

3 Growth Stocks with All-Star Potential

August 07, 2026

Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va...

Via StockStory

Topics Energy

Natera (NASDAQ:NTRA) Reports Strong Q2 CY2026, Stock Jumps 16.3%

August 06, 2026

Genetic testing company Natera (NASDAQ:NTRA) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 37.7% year on year to $752.8 mi...

Via StockStory

Natera Reports Second Quarter 2026 Financial Results

August 06, 2026

From Natera, Inc.

Via Business Wire

Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗

August 05, 2026

Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.85% on an annualized basis producing an average annual return of 38.28%. Currently, Natera has a market capitalization of...

Via Benzinga

Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer

August 05, 2026

From Natera, Inc.

Via Business Wire

Natera (NTRA) Reports Q2: Everything You Need To Know Ahead Of Earnings

August 04, 2026

Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday afternoon. Here’s what investors should know. Natera beat anal...

Via StockStory

Stanley Druckenmiller Put 18% of His $3.4 Billion Portfolio in This One Stock. Is Natera a Buy? ↗

August 04, 2026

The company has made massive strides in medical diagnostics and is growing at a rapid clip.

Via The Motley Fool

Topics Intellectual Property

Natera to Report its Second Quarter Results on August 6, 2026

July 30, 2026

From Natera, Inc.

Via Business Wire

July 27, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

3 Reasons We’re Fans of Natera (NTRA)

July 24, 2026

Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 9.1% to $263.44 per...

Via StockStory

Topics Stocks

Signatera™ MRD Outperformed AMERK Testing in Predicting Merkel Cell Carcinoma Recurrence in JAMA Dermatology Study

July 22, 2026

From Natera, Inc.

Via Business Wire

3 Market-Beating Stocks Worth Your Attention

July 22, 2026

Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that ca...

Via StockStory

Finalized MolDx LCD Includes Expanded Coverage for Natera’s Prospera™ Portfolio

July 16, 2026

From Natera, Inc.

Via Business Wire

Billionaire Stanley Druckenmiller's Top Holding Isn't Nvidia. Instead, It's This Under-the-Radar Stock That Wall Street Loves. ↗

July 16, 2026

It may not be a familiar name, but Natera has provided better returns than Nvidia over the past 12 months.

Via The Motley Fool

Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks

July 15, 2026

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Natera (NASDAQ:NTRA) and its ...

Via StockStory

Topics Artificial Intelligence

1 Cash-Producing Stock with Exciting Potential and 2 We Brush Off

July 10, 2026

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...

Via StockStory

Natera Announces IVDR Certification for Signatera™ Across Multiple Cancers

July 09, 2026

From Natera, Inc.

Via Business Wire

Signatera™ MRD Test Predicted Overall Survival Benefit from Chemotherapy in Resected Metastatic Colorectal Cancer

July 06, 2026

From Natera, Inc.

Via Business Wire

Natera and Aveta Biomics Announce Strategic Partnership Supporting Global Phase 3 Registrational Trial of APG-157 in Head and Neck Cancer

June 29, 2026

From Natera, Inc.

Via Business Wire

Natera and Eledon Announce Strategic Partnership for Prospera™ Monitoring in Planned Phase 3 Kidney Transplant Trial

June 25, 2026

From Natera, Inc.

Via Business Wire

Why Natera (NTRA) Stock Is Up Today

June 24, 2026

What Happened? Shares of genetic testing company Natera (NASDAQ:NTRA). jumped 7.7% in the morning session after the company announced its Signatera test rece...

Via StockStory

Topics Artificial Intelligence

NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update

June 23, 2026

From Natera, Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.